A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease by Salloway S, Sperling R, Gilman S, Fox N C, Blennow K, Raskind M, Sabbagh M, Honig L S, Doody R, van Dyck C H, Mulnard R, Barakos J, Gregg K M, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators in Neurology (2009).

[PMID: 19923550] PubMed

Abstract

Discussed In Paper

Loading...

Dosing Information

No dosing information annotated.